Grit Biotechnology

This early-stage trial tested a treatment that uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack advanced solid tumors. The goal was to check safety and side effects, but the study was stopped early after enrolling only 2 participants. Because the treat…

This early-stage study tested a new treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack advanced lung adenocarcinoma. The trial was open to adults whose cancer had returned after standard chemotherapy. Only 2 people enrolled before the stu…

This early-phase study tested a personalized immune cell therapy called GT201 in one person with advanced gynecological tumors. The treatment uses the patient's own tumor-fighting cells to try to shrink tumors. The study was stopped early, so results are very limited and no concl…

This early-phase trial tested a personalized cell therapy called GT101 for people with advanced solid tumors that had spread or come back. The treatment involved collecting immune cells from the patient's own tumor, growing them in a lab, and infusing them back along with chemoth…

This study tested a personalized treatment called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced lung cancer. The goal was to see if it was safe and could shrink tumors. Only 2 people took part, and the study was stopped early, so res…

This study tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or come back. Doctors took immune cells from each patient's tumor, multiplied them in a lab, and infused them back after a short course of chemotherapy. The goal was to s…

This early study tested an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological tumors like cervical cancer. Only 4 people took part, and the main goal was to check safety and side effects. The stud…

This early-phase study tested a personalized therapy called GT201 for people with advanced solid tumors that have spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and given back along with chemotherapy a…

This study tested a new treatment for advanced non-small cell lung cancer using a patient's own immune cells (TILs) combined with an immunotherapy drug. The goal was to see if the combination was safe and tolerable. However, the trial was terminated early and only enrolled 2 peop…